Saturday 17 October 2026
Export BIORQ’s income statement to Excel — free account
Biora Therapeutics, Inc.
BIORQ Healthcare Biotechnology
Operating cash flow growth for three consecutive years.
0.00
0.00
NaN
Follow BIORQ
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | Trend | 2024e | 2025e | 2026e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | 770.00 | 164.25 | 32.75 | 10.50 |
Analyst estimates 2024–2026 Powerpack |
|||
| High | — | — | — | — | — | — | 3,980.00 | 1,965.00 | 577.50 | 76.80 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | 674 | 649 | 124 | 54 | 58 | ||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.21 | 0.00 | 0.01 | 0.01 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | 128 | 144 | 0 | 1 | 0 | 0 | ||||
| Gross margin, % | — | — | — | — | 28.05 | 30.21 | 100.00 | 100.00 | 100.00 | 100.00 | |||||
| EBT | — | — | — | — | (124) | (149) | (143) | (179) | (49) | (124) | |||||
| EBT margin, % | — | — | — | — | (96.78) | (103.30) | (88,035.80) | (14,325.58) | (16,147.54) | (3,110,600.00) | |||||
| Net income | — | — | — | 0 | (129) | (148) | (193) | (247) | (38) | (124) | |||||
| Depreciation | — | — | — | — | 6 | 6 | 5 | 3 | 2 | 2 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | 69.30 | 7,383.85 | 1.47 | 3.24 | 0.40 | 0.00 | ||||
| Earnings | — | — | — | — | (69.92) | (7,579.20) | (1,752.50) | (642.50) | (50.00) | (78.70) | |||||
| Cash flow | — | — | — | — | (35.27) | (5,442.26) | (1,505.40) | (435.48) | (84.37) | (30.75) | |||||
| Capex | — | — | — | — | 0.00 | (191.03) | (35.16) | (2.22) | (1.04) | (0.06) | |||||
| Free cash flow | — | — | — | — | (35.27) | (5,633.28) | (1,540.55) | (437.70) | (85.41) | (30.81) | |||||
| Book value | — | — | — | — | (20.02) | (4,301.23) | (971.79) | (220.95) | (133.97) | (64.30) | |||||
| Shares, m | — | — | — | — | 2 | 0 | 0 | 0 | 1 | 2 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| P/S | — | — | — | — | 0.58 | 0.58 | 7.64 | 278.35 | 58.83 | 214.06 | |||||
| P/B | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| EV/Sales | — | — | — | — | 1.12 | 1.12 | 9.63 | 308.82 | 380.85 | 525.30 | |||||
| EV/FCF | — | — | — | — | (0.89) | (0.89) | (1.95) | (2.29) | (1.78) | (1.06) | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | (65) | (106) | (166) | (167) | (64) | (48) | ||||
| Capex | — | — | — | — | (5) | (4) | (4) | (1) | (1) | 0 | |||||
| Free cash flow | — | — | — | — | (65) | (110) | (170) | (168) | (65) | (49) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | 11 | (26) | 54 | 37 | 15 | (44) | ||||
| Total debt | — | — | — | — | 73 | 4 | 160 | 126 | 129 | 46 | |||||
| Net debt | — | — | — | — | 4 | (29) | 68 | 38 | 98 | 31 | |||||
| Shareholders’ equity | — | — | — | — | (37) | (84) | (107) | (85) | (102) | (101) | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | (221.84) | (209.81) | (150.52) | (187.95) | (47.00) | (292.93) | ||||
| ROIC | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | — | — | — | 213.45 | 378.33 | 201.91 | 257.76 | 40.75 | 121.86 | |||||
Negative figures in brackets.
Fiscal years to Dec 2023 · latest quarter Sep 2024
Charts ten years each
Biora Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| GOVX GeoVax Labs Inc. | $2.6M | — (loss-making) | — (loss-making) | +183.44% (above 0%: growing) | n/m | +15.81% (above 0%: growing) | 100.00% | 0.00% | Compare |
| XRTX XORTX Therapeutics Inc. | $2.6M | — (loss-making) | — | — | n/m | −318.40% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| EIGRQ Eiger BioPharmaceuticals, Inc. | $2.6M | — (loss-making) | — (loss-making) | +41.06% (above 0%: growing) | n/m | +37.90% (above 0%: growing) | 97.34% | (331.69%) | Compare |
| BIORQ Biora Therapeutics, Inc. | $2.5M | — (loss-making) | — (loss-making) | +1,500.00% (above 0%: growing) | n/m | +20.72% (above 0%: growing) | 100.00% | (50,709.38%) | |
| ELAB PMGC Holdings Inc. | $2.5M | — (loss-making) | — | +147.70% (above 0%: growing) | n/m | −44.95% (below 0%: shrinking) | 29.52% | (292.91%) | Compare |
| NTBLQ Notable Labs, Ltd. | $2.4M | — (loss-making) | — (loss-making) | −96.88% (below 0%: shrinking) | n/m | −26.63% (below 0%: shrinking) | 100.00% | (269,000.00%) | Compare |
| VBIO Valion Bio, Inc. | $2.4M | — (loss-making) | — (loss-making) | +15.87% (above 0%: growing) | n/m | −189.01% (below 0%: shrinking) | (99.32%) | 0.00% | Compare |
| MTNB Matinas Biopharma Holdings, Inc. | $2.4M | — (loss-making) | — (loss-making) | +365,433.33% (above 0%: growing) | n/m | +9.15% (above 0%: growing) | 0.00% | 0.00% | Compare |
| BPTSY Biophytis SA Sponsored ADR | $2.4M | — (loss-making) | — | — | n/m | +53.15% (above 0%: growing) | 0.00% | — | Compare |
| Median of peers | $2.4M | — | — | +94.38% | — | −8.74% | 14.76% | 0.00% |
Biora Therapeutics, Inc. (BIORQ) key facts
- Biora Therapeutics, Inc. (BIORQ) is a Biotechnology company in the Healthcare sector.
- Return on equity was 121.9% and debt-to-equity -0.18.
- Its Piotroski F-score is 2 out of 9 and its Altman Z-score is −51.34 (distress zone) for fiscal 2023.
Biora Therapeutics, Inc. (BIORQ) Latest News
No news at this impact. Lower the threshold for more.